Antidepressant Drugs Market Dynamics 2021-2031
The depression is the mood disorder that give a continue feeling of sadness and loss of interest. There are many factors which leads to the depression such as inherited traits, hormones, stress, brain chemistry which can cause the depression. The antidepressants help to maintain the balance between the brain chemistry and hormonal changes which is used for treatment of depression. Depression require long time of treatment it can be treated by specific treatment or psychotherapy.
MARKET DYNAMICS
The Antidepressant Drugs Market is anticipated to grow in the forecast period owing to driving factors such as increasing geriatric population, increasing prevalence of depression, and development of new drug with minor side effect is driving the growth of market. However the concerns for efficacy and safety of drug and preference to the non-pharmacological therapy harms the growth of market.
MARKET SCOPE
The "Global Antidepressant Drugs Market Analysis to 2031" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of antidepressant drugs market with detailed market segmentation by depressive disorder, product and geography. The global antidepressant drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading antidepressant drugs market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global antidepressant drugs market is segmented on the basis of depressive disorder and product. Based on depressive disorder, the market is segmented as major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, panic disorder, others. On the basis of product, the global antidepressant drugs market is segmented into tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, serotonin antagonist and reuptake inhibitors, others.
REGIONAL FRAMEWORKThe report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global antidepressant drugs market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The antidepressant drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting antidepressant drugs market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the antidepressant drugs market in these regions.
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global antidepressant drugs market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The antidepressant drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting antidepressant drugs market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the antidepressant drugs market in these regions.
MARKET PLAYERSThe reports cover key developments in the antidepressant drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from antidepressant drugs market are anticipated to lucrative growth opportunities in the future with the rising demand for Antidepressant Drugs in the global market. Below mentioned is the list of few companies engaged in the antidepressant drugs market.
The report also includes the profiles of key antidepressant drugs market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Alkermes Plc.
- Allergan Plc.
- Bristol Myers Squibb Co.
- Eli Lilly and Co.
- GlaxoSmithKline Plc.
- H. Lundbeck
- Merck & Co., Inc.
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Co. Ltd.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Antidepressant Drugs - By Depressive Disorder
1.3.2 Antidepressant Drugs - By Product
1.3.3 Antidepressant Drugs - By Region
1.3.3.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. ANTIDEPRESSANT DRUGS LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ANTIDEPRESSANT DRUGS - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. ANTIDEPRESSANT DRUGS - GLOBAL MARKET ANALYSIS
6.1. ANTIDEPRESSANT DRUGS - GLOBAL MARKET OVERVIEW
6.2. ANTIDEPRESSANT DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. ANTIDEPRESSANT DRUGS - REVENUE AND FORECASTS TO 2028 - DEPRESSIVE DISORDER
7.1. OVERVIEW
7.2. DEPRESSIVE DISORDER MARKET FORECASTS AND ANALYSIS
7.3. MAJOR DEPRESSIVE DISORDER
7.3.1. Overview
7.3.2. Major Depressive Disorder Market Forecast and Analysis
7.4. OBSESSIVE-COMPULSIVE DISORDER
7.4.1. Overview
7.4.2. Obsessive-Compulsive Disorder Market Forecast and Analysis
7.5. GENERALIZED ANXIETY DISORDER
7.5.1. Overview
7.5.2. Generalized Anxiety Disorder Market Forecast and Analysis
7.6. PANIC DISORDER
7.6.1. Overview
7.6.2. Panic Disorder Market Forecast and Analysis
7.7. OTHERS
7.7.1. Overview
7.7.2. Others Market Forecast and Analysis
8. ANTIDEPRESSANT DRUGS - REVENUE AND FORECASTS TO 2028 - PRODUCT
8.1. OVERVIEW
8.2. PRODUCT MARKET FORECASTS AND ANALYSIS
8.3. TRICYCLIC ANTIDEPRESSANTS
8.3.1. Overview
8.3.2. Tricyclic Antidepressants Market Forecast and Analysis
8.4. SELECTIVE SEROTONIN REUPTAKE INHIBITORS
8.4.1. Overview
8.4.2. Selective Serotonin Reuptake Inhibitors Market Forecast and Analysis
8.5. SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS
8.5.1. Overview
8.5.2. Serotonin-Norepinephrine Reuptake Inhibitors Market Forecast and Analysis
8.6. MONOAMINE OXIDASE INHIBITORS
8.6.1. Overview
8.6.2. Monoamine Oxidase Inhibitors Market Forecast and Analysis
8.7. SEROTONIN ANTAGONIST AND REUPTAKE INHIBITORS
8.7.1. Overview
8.7.2. Serotonin Antagonist and Reuptake Inhibitors Market Forecast and Analysis
8.8. OTHERS
8.8.1. Overview
8.8.2. Others Market Forecast and Analysis
9. ANTIDEPRESSANT DRUGS REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Antidepressant Drugs Overview
9.1.2 North America Antidepressant Drugs Forecasts and Analysis
9.1.3 North America Antidepressant Drugs Forecasts and Analysis - By Depressive Disorder
9.1.4 North America Antidepressant Drugs Forecasts and Analysis - By Product
9.1.5 North America Antidepressant Drugs Forecasts and Analysis - By Countries
9.1.5.1 United States Antidepressant Drugs
9.1.5.1.1 United States Antidepressant Drugs by Depressive Disorder
9.1.5.1.2 United States Antidepressant Drugs by Product
9.1.5.2 Canada Antidepressant Drugs
9.1.5.2.1 Canada Antidepressant Drugs by Depressive Disorder
9.1.5.2.2 Canada Antidepressant Drugs by Product
9.1.5.3 Mexico Antidepressant Drugs
9.1.5.3.1 Mexico Antidepressant Drugs by Depressive Disorder
9.1.5.3.2 Mexico Antidepressant Drugs by Product
9.2. EUROPE
9.2.1 Europe Antidepressant Drugs Overview
9.2.2 Europe Antidepressant Drugs Forecasts and Analysis
9.2.3 Europe Antidepressant Drugs Forecasts and Analysis - By Depressive Disorder
9.2.4 Europe Antidepressant Drugs Forecasts and Analysis - By Product
9.2.5 Europe Antidepressant Drugs Forecasts and Analysis - By Countries
9.2.5.1 Germany Antidepressant Drugs
9.2.5.1.1 Germany Antidepressant Drugs by Depressive Disorder
9.2.5.1.2 Germany Antidepressant Drugs by Product
9.2.5.2 France Antidepressant Drugs
9.2.5.2.1 France Antidepressant Drugs by Depressive Disorder
9.2.5.2.2 France Antidepressant Drugs by Product
9.2.5.3 Italy Antidepressant Drugs
9.2.5.3.1 Italy Antidepressant Drugs by Depressive Disorder
9.2.5.3.2 Italy Antidepressant Drugs by Product
9.2.5.4 Spain Antidepressant Drugs
9.2.5.4.1 Spain Antidepressant Drugs by Depressive Disorder
9.2.5.4.2 Spain Antidepressant Drugs by Product
9.2.5.5 United Kingdom Antidepressant Drugs
9.2.5.5.1 United Kingdom Antidepressant Drugs by Depressive Disorder
9.2.5.5.2 United Kingdom Antidepressant Drugs by Product
9.2.5.6 Rest of Europe Antidepressant Drugs
9.2.5.6.1 Rest of Europe Antidepressant Drugs by Depressive Disorder
9.2.5.6.2 Rest of Europe Antidepressant Drugs by Product
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Antidepressant Drugs Overview
9.3.2 Asia-Pacific Antidepressant Drugs Forecasts and Analysis
9.3.3 Asia-Pacific Antidepressant Drugs Forecasts and Analysis - By Depressive Disorder
9.3.4 Asia-Pacific Antidepressant Drugs Forecasts and Analysis - By Product
9.3.5 Asia-Pacific Antidepressant Drugs Forecasts and Analysis - By Countries
9.3.5.1 Australia Antidepressant Drugs
9.3.5.1.1 Australia Antidepressant Drugs by Depressive Disorder
9.3.5.1.2 Australia Antidepressant Drugs by Product
9.3.5.2 China Antidepressant Drugs
9.3.5.2.1 China Antidepressant Drugs by Depressive Disorder
9.3.5.2.2 China Antidepressant Drugs by Product
9.3.5.3 India Antidepressant Drugs
9.3.5.3.1 India Antidepressant Drugs by Depressive Disorder
9.3.5.3.2 India Antidepressant Drugs by Product
9.3.5.4 Japan Antidepressant Drugs
9.3.5.4.1 Japan Antidepressant Drugs by Depressive Disorder
9.3.5.4.2 Japan Antidepressant Drugs by Product
9.3.5.5 South Korea Antidepressant Drugs
9.3.5.5.1 South Korea Antidepressant Drugs by Depressive Disorder
9.3.5.5.2 South Korea Antidepressant Drugs by Product
9.3.5.6 Rest of Asia-Pacific Antidepressant Drugs
9.3.5.6.1 Rest of Asia-Pacific Antidepressant Drugs by Depressive Disorder
9.3.5.6.2 Rest of Asia-Pacific Antidepressant Drugs by Product
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Antidepressant Drugs Overview
9.4.2 Middle East and Africa Antidepressant Drugs Forecasts and Analysis
9.4.3 Middle East and Africa Antidepressant Drugs Forecasts and Analysis - By Depressive Disorder
9.4.4 Middle East and Africa Antidepressant Drugs Forecasts and Analysis - By Product
9.4.5 Middle East and Africa Antidepressant Drugs Forecasts and Analysis - By Countries
9.4.5.1 South Africa Antidepressant Drugs
9.4.5.1.1 South Africa Antidepressant Drugs by Depressive Disorder
9.4.5.1.2 South Africa Antidepressant Drugs by Product
9.4.5.2 Saudi Arabia Antidepressant Drugs
9.4.5.2.1 Saudi Arabia Antidepressant Drugs by Depressive Disorder
9.4.5.2.2 Saudi Arabia Antidepressant Drugs by Product
9.4.5.3 U.A.E Antidepressant Drugs
9.4.5.3.1 U.A.E Antidepressant Drugs by Depressive Disorder
9.4.5.3.2 U.A.E Antidepressant Drugs by Product
9.4.5.4 Rest of Middle East and Africa Antidepressant Drugs
9.4.5.4.1 Rest of Middle East and Africa Antidepressant Drugs by Depressive Disorder
9.4.5.4.2 Rest of Middle East and Africa Antidepressant Drugs by Product
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Antidepressant Drugs Overview
9.5.2 South and Central America Antidepressant Drugs Forecasts and Analysis
9.5.3 South and Central America Antidepressant Drugs Forecasts and Analysis - By Depressive Disorder
9.5.4 South and Central America Antidepressant Drugs Forecasts and Analysis - By Product
9.5.5 South and Central America Antidepressant Drugs Forecasts and Analysis - By Countries
9.5.5.1 Brazil Antidepressant Drugs
9.5.5.1.1 Brazil Antidepressant Drugs by Depressive Disorder
9.5.5.1.2 Brazil Antidepressant Drugs by Product
9.5.5.2 Argentina Antidepressant Drugs
9.5.5.2.1 Argentina Antidepressant Drugs by Depressive Disorder
9.5.5.2.2 Argentina Antidepressant Drugs by Product
9.5.5.3 Rest of South and Central America Antidepressant Drugs
9.5.5.3.1 Rest of South and Central America Antidepressant Drugs by Depressive Disorder
9.5.5.3.2 Rest of South and Central America Antidepressant Drugs by Product
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. ANTIDEPRESSANT DRUGS, KEY COMPANY PROFILES
11.1. ALKERMES PLC
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. ALLERGAN PLC
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. BRISTOL MYERS SQUIBB CO.
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. ELI LILLY AND CO.
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. GLAXOSMITHKLINE PLC
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. H. LUNDBECK
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. MERCK & CO., INC.
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. PFIZER INC.
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. TEVA PHARMACEUTICAL INDUSTRIES LTD.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. TAKEDA PHARMACEUTICAL CO. LTD.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
1. Alkermes Plc.
2. Allergan Plc.
3. Bristol Myers Squibb Co.
4. Eli Lilly and Co.
5. GlaxoSmithKline Plc.
6. H. Lundbeck
7. Merck & Co., Inc.
8. Pfizer Inc.
9. Teva Pharmaceutical Industries Ltd.
10. Takeda Pharmaceutical Co. Ltd.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For